Strong Continuous Non-malleable Encoding Schemes with Tamper-Detection

A non-malleable encoding scheme is a keyless encoding scheme which is resilient to tampering attacks. Such a scheme is said to be continuously secure if the scheme is resilient to attacks containing more than one tampering procedure. Also, such a scheme is said to have tamper-detection property if any kind of tampering attack is detected. In [S. Faust, et al., Continuous nonmalleable codes, TCC Proc., LNCS Vol. 8349, 2014.] a general continuous non-malleable encoding scheme based on NIZK is introduced which is secure in a strong model for which the adversary receives a no-tamper as a response to its tampering query if the decoding of the tampered codeword is identical to the original message. In this article we introduce a new strongly secure continuous non-malleable encoding scheme with tamper-detection property whose security is based on the existence of secure MAC’s. Moreover, we introduce and justify the importance of an intermediate security model called semi-strong continuous non-malleability, while we provide a secure semi-strong continuous non-malleable encoding scheme whose security is based on the existence of CCA-secure public-key encryption. Considering the area of applications of encoding schemes in tamper-proof devices, it is instructive to note that our proposed schemes can be used to implement an algorithmic tamperdetection level as well as maintaining the security conditions

Cryptanalysis and Security Enhancement on the Generation of Mu-Varadharajan Electronic Voting Protocol

Mu and Varadharajan proposed an electronic voting scheme and claimed that their scheme authenticates the voters, protects the anonymity of them, and detects the identity of double voters. Due to some weaknesses in Mu-Varadharajan scheme, several modified schemes have been proposed by Lin et al., Hwang et al., Rodriguez-Henriquez et al. and Asaar et al.; however this paper shows that these schemes suffer from some weaknesses in fulfilling the pointed properties. For this purpose, we get Hwang et al. scheme as a case study and apply our new attacks on it. Also we consider the applicability of the attacks on other pointed schemes. In addition, we present a new scheme and show that the scheme resists against the proposed attacks without loosing efficiency

Double Voter Perceptible Blind Signature Based Electronic Voting Protocol

Mu et al. have proposed an electronic voting protocol and claimed that it protects anonymity of voters, detects double voting and authenticates eligible voters. It has been shown that it does not protect voter\u27s privacy and prevent double voting. After that, several schemes have been presented to fulfill these properties. However, many of them suffer from the same weaknesses. In this paper, getting Asadpour et al. scheme as one of the latest one and showing its weaknesses, we propose a new voting scheme which is immune to the weaknesses of previous schemes without loosing efficiency. The scheme, is based on a special structure, which directly use the identity of voter, hides it in that structure and reveals it after double voting. We also, show that the security of this scheme depends on hardness of RSA cryptosystem, Discrete Logarithm problem and Representation problem

A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Purpose: Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixonaline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. Experimental design: Eligible patients with metastatic or recurrent colorectal cancer received CQS at a dose schedule of 2000 mg/m 2 over an hour weekly for 4 weeks every 42 days. Treatment was continued until unexpected toxicity or disease progression. Results: A total of seventeen patients were enrolled on this study. 94% of all patients enrolled had prior treatment. Sixteen patients were evaluable for response with fifteen patients showing evidence of disease progression and one patient with prolonged stable disease. One patient had non-evaluable disease. Following this interim analysis, the drug was considered ineffective and the study was terminated early. The most frequent adverse event was anemia. No patients discontinued the treatment because of toxicity. Conclusion: CQS, when given at a dose of 2000 mg/m 2 weekly for 4 weeks every 42 days to patients with metastatic colorectal cancer, does not result in significant tumor regression.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43416/1/10637_2005_Article_4827.pd

Ruthenium oxide-carbon-based nanofiller-reinforced conducting polymer nanocomposites and their supercapacitor applications.

In this review article, we have presented for the first time the new applications of supercapacitor technologies and working principles of the family of RuO2-carbon-based nanofiller-reinforced conducting polymer nanocomposites. Our review focuses on pseudocapacitors and symmetric and asymmetric supercapacitors. Over the last years, the supercapacitors as a new technology in energy storage systems have attracted more and more attention. They have some unique characteristics such as fast charge/discharge capability, high energy and power densities, and long stability. However, the need for economic, compatible, and easy synthesis materials for supercapacitors have led to the development of RuO2-carbon-based nanofiller-reinforced conducting polymer nanocomposites with RuO2. Therefore, the aim of this manuscript was to review RuO2-carbon-based nanofiller-reinforced conducting polymer nanocomposites with RuO2 over the last 17 years

The assessment of function, histopathological changes, and oxidative stress in liver tissue due to ionizing and non-ionizing radiations

Background: Compared to past decades, humans are exposed to rapidly increasing levels of radiofrequency electromagnetic radiations (RF-EMF). Despite numerous studies, the biological effects of human exposure to different levels of RF-EMF are not fully understood yet. This study aimed to evaluate the bioeffects of exposure to "900/1800 MHz" and “2.4 GHz" RF-EMFs, and x-rays alone as well as their potential interactions, i.e. inducing simple additive, adaptive, or synergistic effects. Methods: 120 Wistar rats were randomly divided into ten groups of 12 each. The rats were exposed to RF-EMF, 10 cGy, and 8 Gy x-rays, a combination of these exposures, or only sham-exposed. The levels of liver enzymes were determined in serum samples by an autoanalyzer. Moreover, the histopathological changes, and the levels of malondialdehyde (MDA), nitric oxide, ferric reducing antioxidant power, total thiols, and protein carbonyl (PCO) were measured. Results: Among the markers of liver function, gamma-glutamyltransferase was not associated with irradiation but, aspartate transaminase, alanine transaminase, and alkaline phosphatase showed some levels of association. MDA and PCO levels after 8 Gy irradiation increased, but pre-exposure to RF-EMF could modulate their changes. At the cellular level, the frequency of lobular inflammation was associated with the type of intervention. Conclusion: The exposure to both ionizing and non-ionizing radiations could alter some liver function tests. A short term pre-exposure to RF-EMF before exposure to an 8 Gy challenging dose of x-rays caused the alterations in oxidative stress markers and liver function tests, which indicate that oxidative stress is possibly involved in the adaptive response

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Between December 2015 and November 2018, 108 patients were randomly assigned to pembrolizumab (n = 55) or placebo (n = 53). The objective response rate was 23% with pembrolizumab and 10% with placebo. Treatment-emergent grade 3-4 adverse events occurred in 59% receiving pembrolizumab and 38% of patients receiving placebo. Progression-free survival was significantly longer with maintenance pembrolizumab versus placebo (5.4 months [95% CI, 3.1 to 7.3 months] v 3.0 months [95% CI; 2.7 to 5.5 months]; hazard ratio, 0.65; log-rank P = .04; maximum efficiency robust test P = .039). Median overall survival was 22 months (95% CI, 12.9 months to not reached) with pembrolizumab and 18.7 months (95% CI, 11.4 months to not reached) with placebo. There was no significant interaction between PD-L1 CPS ≥ 10 and treatment arm for progression-free survival or overall survival.12 month embargo; first published online 9 April 2020This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]